A retrospective study to characterize thyroid function test abnormalities and evaluating clinical outcomes in patients with several neoplasm who treated with pembrolizumab, nivolumab and ipilimumab
Latest Information Update: 23 Mar 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Hodgkin's disease; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Mar 2021 New trial record
- 01 Feb 2021 Results published in the Cancer Immunology Immunotherapy